Education
About Us
Working with TipRanks
Follow Us
Vivani Medical (VANI)
NASDAQ:VANI
VANI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.91 - $1.80
Previous CloseN/A
Volume36.09K
Average Volume (3M)163.19K
Market Cap
$81.16M
Enterprise Value$88.25M
Total Cash (Recent Filing)$6.79M
Total Debt (Recent Filing)$18.62M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 18, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding59,243,904
10 Day Avg. Volume115,776
30 Day Avg. Volume163,195
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)3.62
Price to Sales (P/S)0.00
P/FCF Ratio-2.99
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue221.73
Enterprise Value/Gross Profit-5.88K
Enterprise Value/Ebitda-3.33
Forecast
1Y Price Target
$4.00Price Target Upside183.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Market OpportunityVivani is developing a potential 6-month semaglutide implant for weight loss, which could offer a significant market opportunity due to the lack of compliance with weekly injections.
Product DifferentiationNPM-139 is the only 6-month implant which provides significant differentiation as it eliminates the need for weekly injectables or daily orals.
Regulatory And Investor ConfidenceSemaglutide, the active ingredient in NPM-139, is already well-known for its weight loss and safety profile, which could benefit future regulatory filings and investor familiarity.
Bears Say
Clinical And Regulatory RisksRisks include failure of NPM-139 in clinical trials, failure to secure regulatory approval, failure to achieve commercial success, and dilution risk.
Strategic Focus And Resource AllocationVivani will strategically prioritize development of NPM-139 (semaglutide) over NPM-115 for treating obesity and will advance NPM-139 into the next clinical studies.
Vivani Medical News
VANI FAQ
What was Vivani Medical’s price range in the past 12 months?
Vivani Medical lowest stock price was $0.91 and its highest was $1.80 in the past 12 months.
What is Vivani Medical’s market cap?
Vivani Medical’s market cap is $81.16M.
When is Vivani Medical’s upcoming earnings report date?
Vivani Medical’s upcoming earnings report date is Nov 18, 2025 which is in 39 days.
How were Vivani Medical’s earnings last quarter?
Vivani Medical released its earnings results on Aug 13, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.1 by -$0.02.
Is Vivani Medical overvalued?
According to Wall Street analysts Vivani Medical’s price is currently Undervalued.
Does Vivani Medical pay dividends?
Vivani Medical does not currently pay dividends.
What is Vivani Medical’s EPS estimate?
Vivani Medical’s EPS estimate is -0.11.
How many shares outstanding does Vivani Medical have?
Vivani Medical has 59,243,904 shares outstanding.
What happened to Vivani Medical’s price movement after its last earnings report?
Vivani Medical reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.1. Following the earnings report the stock price went up 0.794%.
Which hedge fund is a major shareholder of Vivani Medical?
Currently, no hedge funds are holding shares in VANI
Vivani Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (183.69% Upside)
$4.00 (183.69% Upside)
Insider Transactions
Bought Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 9.2%
Last 30 Days ▲ 9.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.12%
12-Months-Change
Fundamentals
Return on Equity
-177.75%
Trailing 12-Months
Asset Growth
-40.06%
Trailing 12-Months
Company Description
Vivani Medical
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
VANI Stock 12 Month Forecast
Average Price Target
$4.00
▲(183.69% Upside)
Technical Analysis
Ownership Overview
30.22% Insiders
2.95% Mutual Funds
2.45% Other Institutional Investors
62.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---